Multiple system atrophy (MSA) is an adult-onset sporadic neurodegenerative disorder of unknown etiology featuring parkinsonism, ataxia, and autonomic failure in any combination. Because disease progression in MSA is rapid and no drug treatment consistently benefits MSA patients in the long term, neuroprotective or regenerative strategies may be invaluable in the management of MSA patients. In this study, we investigated whether human mesenchymal stem cells (hMSCs) had a protective effect on MSA using an animal model of double-toxin-induced MSA parkinsonism (MSA-P). MSA-P was established with coinjections of MPTP and 3-NP; hMSCs were injected into the tail vein 1 day after the last toxin injection. Three groups of mice were compared (i.e., control, MPTP + 3-NP, and MPTP + 3-NP with hMSC treatment) through histopathological, behavioral, and Western blot analyses. In the substantia nigra (SN) and the striatum, 2.0% and 3.8% of total injected hMSCs were observed, respectively. Compared with double-toxin-treated mice, hMSC treatment in double-toxin-treated mice significantly increased survival of TH-and NeuN-immunoreactive cells in the SN and the striatum, with coincident improvement in motor behavior. Additionally, hMSC treatment significantly decreased double-toxin-induced microglial and astroglial activation in the SN and striatum. Western blot analysis showed that hMSC administration in double-toxin-treated mice increased the expression of p-Akt and Bcl-2 and decreased Bax and cytochrome c expression. This study demonstrates that hMSC treatment protected against loss of neurons in the SN and the striatum induced by double toxin exposure, which may be mediated by modulation of inflammatory and cell survival and death signalingpathway as the hMSCs migrated from the peripheral circulation into the SN and striatum. The animal model of MSA-P is based on the concept The pole test was performed according to a previous study (17). Each mouse was placed on the top of a vertiof inducing selective degeneration in nigral and striatal neurons by using 1-methyl-4-phenyl-1,2,3,6 tetrahydrocal wooden rough-surfaced pole (1-cm diameter; 50-cm height). On the day prior to testing, mice were habitupyridine (MPTP) and 3-nitropropionic acid (3-NP), which were previously used to mimic Parkinson's disated to the apparatus by placing them at the top of the pole and allowing them to descend five times. The total ease and Huntington's disease, respectively, in rodents (24). In this double lesion model, the MPTP is known time that it took each mouse to reach the base of the pole and place all four paws on the floor was recorded. to potentiate striatal damage and behavioral impairments induced by 3-NP intoxication and thus constitute a useFor each session of five descents, the best performance was recorded as the total time. If the mouse was unable ful model of MSA-P. In the present study, we investigated whether hMSCs had a protective effect against to turn completely downward, fell off, or slipped down the pole, a default value of 120 s w...